In order to understand the potential immune mechanisms in relieving hypoxia activated by combined RT‐RDT‐immunotherapy with Hb@Hf‐Ce6 NPs, innate immune responses in both primary and distant tumors were assessed by flow cytometry on day 10 after three rounds of treatments on an orthotopic combined bilateral tumor model. This evidence concerns the gene GSTM1 and neoplasm.